SCHEMBL25599374

SCHEMBL25599374

C=C1CC(C)CC(CCC(NC(=O)c2ccc3ccccc3c2OCc2ccc(C(F)(F)F)cc2)C(=O)O)C1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.51
KIFC1 Q9BW19 1/20 0.38
MCHR1 Q99705 2/20 0.36
MME P08473 1/20 0.36
ACE P12821 1/20 0.36
CPA1 P15085 1/20 0.36
ACE2 Q9BYF1 1/20 0.36
DRD4 P21917 1/20 0.35
TACR1 P25103 1/20 0.35
UGCG Q16739 3/20 0.34
YAP1 P46937 2/20 0.34
TGM2 P21980 1/20 0.34
PTPN1 P18031 2/20 0.34
SLC6A5 Q9Y345 1/20 0.34
CYP3A4 P08684 1/20 0.34
GPR132 Q9UNW8 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25599284 1.00 CXCR2 (0.51) CXCR2KIFC1MCHR1MMEACE
SCHEMBL25599246 0.94 CXCR2 (0.45) CXCR2KIFC1MCHR1YAP1PTPN1
SCHEMBL25599106 0.92 CXCR2 (0.42) CXCR2KIFC1MMEACECPA1
SCHEMBL25599410 0.92 CXCR2 (0.47) CXCR2KIFC1MCHR1MMEACE
SCHEMBL25599046 0.91 CXCR2 (0.41) CXCR2YAP1PTPN1GPR132
SCHEMBL25599423 0.91 CXCR2 (0.41) CXCR2KIFC1MMEACECPA1
SCHEMBL25599229 0.91 CXCR2 (0.41) CXCR2KIFC1MMEACECPA1
SCHEMBL25599010 0.91 CXCR2 (0.41) CXCR2KIFC1YAP1PTPN1
SCHEMBL25599537 0.91 CXCR2 (0.41) CXCR2KIFC1MMEACECPA1
SCHEMBL25599341 0.90 CXCR2 (0.40) CXCR2KIFC1YAP1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885KIFC1 4789/4885MCHR1 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.